Meeting
2016 ASCO Annual Meeting
Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL).
Authors
Ghayas C. Issa
The University of Texas MD Anderson Cancer Center, Houston, TX
Ghayas C. Issa , Hagop M. Kantarjian , Farhad Ravandi , Deborah A. Thomas , Maria Khouri , Guillermo Garcia-Manero , Rebecca S. Garris , Jorge E. Cortes , Nicholas James Short , Koji Sasaki , Heather M Schroeder , Tapan M. Kadia , Srdan Verstovsek , Naval Guastad Daver , Nitin Jain , Marina Konopleva , Susan Mary O'Brien , Elias Jabbour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT01363128
Citation
J Clin Oncol 34, 2016 (suppl; abstr 7042)
DOI
10.1200/JCO.2016.34.15_suppl.7042
Abstract #
7042
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia.
First Author: Abhishek Maiti
Poster
2018 ASCO Annual Meeting
A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.
First Author: Abdul Hamid Bazarbachi
Poster
2017 ASCO Annual Meeting
Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia.
First Author: Nicholas James Short
Poster
2022 ASCO Annual Meeting
A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).
First Author: Nicholas James Short